Camille Martin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4253763/publications.pdf

Version: 2024-02-01

1163117 1372567 9 181 8 10 citations h-index g-index papers 11 11 11 231 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Palladium-Catalyzed Amination of <i>N</i> -Free 2-Chloro-7-azaindole. Organic Letters, 2015, 17, 4710-4713.	4.6	42
2	Impact of cathepsin B-sensitive triggers and hydrophilic linkers on <i>in vitro</i> efficacy of novel site-specific antibody–drug conjugates. Organic and Biomolecular Chemistry, 2018, 16, 1882-1889.	2.8	38
3	Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer <i>in Vitro</i> . Bioconjugate Chemistry, 2018, 29, 3516-3521.	3.6	20
4	Innovative Bioconjugation Technology for Antibody–Drug Conjugates: Proof of Concept in a CD30-Positive Lymphoma Mouse Model. Bioconjugate Chemistry, 2021, 32, 595-606.	3.6	13
5	Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology. Cancers, 2022, 14, 778.	3.7	13
6	Impact of Site-Specific Conjugation of ScFv to Multifunctional Nanomedicines Using Second Generation Maleimide. Bioconjugate Chemistry, 2018, 29, 1553-1559.	3.6	10
7	Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody–Drug Conjugates. ACS Omega, 2020, 5, 1557-1565.	3.5	10
8	In Vitro Characterization and Stability Profiles of Antibody–Fluorophore Conjugates Derived from Interchain Cysteine Cross-Linking or Lysine Bioconjugation. Pharmaceuticals, 2019, 12, 176.	3.8	8
9	Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer. Bioconjugate Chemistry, 2022, 33, 418-426.	3.6	3